» Articles » PMID: 20890618

Iron Mediates Neuritic Tree Collapse in Mesencephalic Neurons Treated with 1-methyl-4-phenylpyridinium (MPP+)

Overview
Specialties Neurology
Physiology
Date 2010 Oct 5
PMID 20890618
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Studies in post-mortem tissues of patients with Parkinson's disease (PD) and in mice treated with 6-hydroxydopamine have shown a decrease in the length of axon and dendrites of striatal neurons. However, the etiology of the morphological changes and their relationship to inhibition of mitochondrial complex I and the cellular levels of iron and glutathione (GSH) have not been described. In this study, we characterized the effect of MPP+, an inhibitor of mitochondria complex I, on the integrity of the neuritic tree of midbrain dopaminergic neurons, and determined the influence of iron and cellular levels of GSH on this degeneration. Sub-maximal concentrations of MPP+ induced a drastic dose-dependent reduction of neurites, without modification of the soma or apparent cell death. Concurrent treatment with MPP+ and non-toxic concentrations of iron accelerated the process of degeneration, whereas neurons grown on a medium low in iron showed enhanced resistance to MPP+ treatment. MPP+-induced neurite shortening depended on the redox state of neurons. Pre-treatment with the general antioxidant N-acetyl cysteine protected neurons from degeneration. Treatment with sub-maximal concentrations of the inhibitor of GSH synthesis buthionine sulfoximine (BSO), in conjunction with iron and MPP+, produced massive cell death, whereas treatment with BSO plus MPP+ under low iron conditions did not damage neurons. These results suggest that under conditions of inhibition of mitochondrial complex I caused by MPP+, the accumulation of iron and the concurrent decrease in GSH results in the loss of the dendritic tree prior to cell death, of dopaminergic neurons in PD.

Citing Articles

Mechanistic Insights Expatiating the Redox-Active-Metal-Mediated Neuronal Degeneration in Parkinson's Disease.

Behl T, Madaan P, Sehgal A, Singh S, Anwer M, Makeen H Int J Mol Sci. 2022; 23(2).

PMID: 35054862 PMC: 8776156. DOI: 10.3390/ijms23020678.


Progressive parkinsonism due to mitochondrial impairment: Lessons from the MitoPark mouse model.

Beckstead M, Howell R Exp Neurol. 2021; 341:113707.

PMID: 33753138 PMC: 8169575. DOI: 10.1016/j.expneurol.2021.113707.


Air pollutants disrupt iron homeostasis to impact oxidant generation, biological effects, and tissue injury.

Ghio A, Soukup J, Dailey L, Madden M Free Radic Biol Med. 2020; 151:38-55.

PMID: 32092410 PMC: 8274387. DOI: 10.1016/j.freeradbiomed.2020.02.007.


Progressively disrupted somatodendritic morphology in dopamine neurons in a mouse Parkinson's model.

Lynch W, Tschumi C, Sharpe A, Branch S, Chen C, Ge G Mov Disord. 2018; 33(12):1928-1937.

PMID: 30440089 PMC: 6492291. DOI: 10.1002/mds.27541.


Iron Chelators and Antioxidants Regenerate Neuritic Tree and Nigrostriatal Fibers of MPP+/MPTP-Lesioned Dopaminergic Neurons.

Aguirre P, Mena N, Carrasco C, Munoz Y, Perez-Henriquez P, Morales R PLoS One. 2015; 10(12):e0144848.

PMID: 26658949 PMC: 4684383. DOI: 10.1371/journal.pone.0144848.


References
1.
Brouard A, Pelaprat D, Dana C, Vial M, Lhiaubet A, Rostene W . Mesencephalic dopaminergic neurons in primary cultures express functional neurotensin receptors. J Neurosci. 1992; 12(4):1409-15. PMC: 6575810. View

2.
Sofic E, Riederer P, Heinsen H, Beckmann H, Reynolds G, Hebenstreit G . Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain. J Neural Transm. 1988; 74(3):199-205. DOI: 10.1007/BF01244786. View

3.
Coleman M . Axon degeneration mechanisms: commonality amid diversity. Nat Rev Neurosci. 2005; 6(11):889-98. DOI: 10.1038/nrn1788. View

4.
Berg D, Youdim M . Role of iron in neurodegenerative disorders. Top Magn Reson Imaging. 2006; 17(1):5-17. DOI: 10.1097/01.rmr.0000245461.90406.ad. View

5.
Perry G, Taddeo M, Petersen R, Castellani R, Harris P, Siedlak S . Adventiously-bound redox active iron and copper are at the center of oxidative damage in Alzheimer disease. Biometals. 2003; 16(1):77-81. DOI: 10.1023/a:1020731021276. View